Built on decades of cell-based product expertise, New York Blood Center Enterprises is expanding its legacy into regenerative medicine with a clinical and research-grade iPS cell line derived from a clinically reconsented cord blood unit.
As an extension of our 61K unit cord blood bank and our expertise in developing the first FDA-approved allogenic stem cell product, this HLA-homozygous line is manufactured under GMP conditions to provide meaningful U.S. population coverage as a high-quality starting material for scalable cell therapy development.
Connect with NYBCe
Thank you for your interest in New York Blood Center Enterprises’ homozygous clinical and research-grade iPS cell line. Complete the form below, and a member of our team will follow up with additional information.